RxDoctor Payments DataLook up a doctor →

Mark Dougherty, MD

Infectious Disease · Lexington, KYNPI 1326049628

Payments from drug & device makers

$11,527in general payments, 2019–2025

Across 555 payments — averaging $20.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$3K
  • Viiv Healthcare Company$1K
  • Shionogi Inc$1K
  • Insmed, Inc.$1K
  • Merck$950
  • Astellas Pharma US Inc$802
  • plus $3K from 22 others

What the payments were for

  • Travel & lodging$1021%
  • Food & beverage$11,06796%
  • Education$3583%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,527 in reported general payments places this provider in the 80th percentile of 100 infectious disease providers in Kentucky.

See all infectious disease providers in Kentucky

Medicare billing

Part B allowed, 2024
$240,460
Medicare patients
292
Services billed
103,869

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TriumeqAbacavir/Dolutegravir/Lamivudi40$155,183
BiktarvyBictegrav/Emtricit/Tenofov Ala23$89,908
ErtapenemErtapenem Sodium17$9,430
Daptomycin18$6,389
Vancomycin Hcl11$5,129
Epinephrine22$3,882
Cefpodoxime Proxetil12$3,052
Piperacillin-TazobactamPiperacillin Sodium/Tazobactam12$2,536
Doxycycline Hyclate79$1,774
Methenamine Hippurate19$1,659
CeftriaxoneCeftriaxone Sodium23$1,322
Minocycline Hcl20$950
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav44$888
Amoxicillin45$780
CefuroximeCefuroxime Axetil15$764

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyTriumeq$1,438$155,18340 claims
GileadBiktarvy$2,647$89,90823 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 100 infectious disease providers in Kentucky.

Other infectious disease in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →